Collagenase Effective for Recurrent Dupuytren - Summary - MDSpire

Collagenase Effective for Recurrent Dupuytren

  • By

  • Alun Evans

  • March 11, 2026

  • 3 min

Share

Objective:

To evaluate the safety and efficacy of collagenase clostridium histolyticum (CCH) injections for treating recurrent Dupuytren contracture after prior surgery.

Key Findings:
  • Mean contracture improved by 43° at first evaluation and remained improved by 38° at final evaluation.
  • Clinical success (contracture reduced to 0°-5°) achieved in 65% of joints at first evaluation and 58% at final evaluation.
  • Outcomes were better in metacarpophalangeal (MP) joints (75% success) compared to proximal interphalangeal (PIP) joints (43% success).
  • Adverse events occurred in 36% of patients, with skin tears being the most common complication.
Interpretation:

Collagenase injection appears to be a safe and effective alternative for patients with recurrent Dupuytren contracture, offering substantial improvement in joint extension and lower complication risks compared to repeat surgery.

Limitations:
  • Retrospective nature of the study may introduce bias.
  • Limited long-term follow-up data.
Conclusion:

CCH treatment for postsurgical recurrence of Dupuytren contracture is effective and well tolerated, providing a viable option for patients wishing to avoid repeat surgery.

Original Source(s)

Related Content